Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety

Deep Origin partners with Ginkgo Bioworks on ARPA-H–funded PREDICTS program to advance computational drug safety

Deep Origin announced a strategic partnership with Ginkgo Bioworks as part of the ARPA-H CATALYST program, a 4.5-year federal initiative to develop next-generation computational platforms for drug safety. Led by Deep Origin, the PREDICTS (Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation) project aims to integrate high-throughput biological data with advanced AI models to better predict toxicity and human safety earlier in drug development.

Through the collaboration, Ginkgo contributes large-scale, high-quality in vitro datasets—spanning small-molecule and genetic perturbations across diverse cell and tissue types—to support Deep Origin’s multi-organ, multi-scale modeling efforts. The partnership represents a major step toward building a virtual human safety framework that could reduce reliance on animal testing and improve translational predictivity in drug discovery.

‍